FDA approves drug for haemophilia B

The US Food and Drug Administration has approved a new medicine for haemophilia B – the first treatment for the disorder to require less frequent injections. The drug, Alprolix, was developed by Biogen Idec Inc and Swedish Orphan Biovitrum AB.